EGFR and non-small cell lung carcinoma: We found that TP53 mutation was the most frequently identified co-occurring genomic alteration in uncommon EGFR-mutant NSCLC, with an incidence rate of 59% (30/51), which is consistent with the reported 40–60% incidence of TP53 co-mutations in EGFR mutation-positive patients in previous studies (17, 31, 32).